A REPLICATIVE ONCOLYTIC ADENOVIRUS CAPABLE OF INHIBITING TUMOR PROGRESSION AND PROLONGING SURVIVAL TIME IN TUMOR-BEARING INDIVIDUALS AND USE THEREOF

Provided are a recombinant adenovirus or adenoviral vector expressing GLP1 receptor agonist that shows expected anti-tumor effects and prolonged survival time in tumor-bearing subjects and the pharmaceutical composition comprising the same. L'invention concerne un adénovirus recombinant ou un v...

Full description

Saved in:
Bibliographic Details
Main Author WEI, Jiwu
Format Patent
LanguageEnglish
French
Published 15.02.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Provided are a recombinant adenovirus or adenoviral vector expressing GLP1 receptor agonist that shows expected anti-tumor effects and prolonged survival time in tumor-bearing subjects and the pharmaceutical composition comprising the same. L'invention concerne un adénovirus recombinant ou un vecteur adénoviral exprimant un agoniste du récepteur GLP1 qui présente des effets anti-tumoraux attendus et un temps de survie prolongé chez des sujets porteurs de tumeurs et une composition pharmaceutique le comprenant.
Bibliography:Application Number: WO2022CN110988